Other resources:

PBAC

• About PBAC
• Procedure Guidance
• PBS Process Improvements
• Cost Recovery Fees and Charges
• Pricing Matters
• PBS Forms
• Elements of the Listing Process
• PBAC Calendar
• PBAC Guidelines
• Utilisation and Cost Model Workbook
• PBAC Resource Use Book
• Restriction Template
• PBAC PSDs
• PBAC Outcomes
• PBAC Agenda
• PBAC Membership
• ESC Membership
• DUSC Membership

MSAC

• About MSAC
• MSAC Assessments
• MSAC Guidelines
• MSAC ADAR Template:
• MSAC DCAR Template:
• MSAC Application Form:
• MSAC Application Form Instructions:
• Clinical Utility Card
• MSAC Membership
• ESC Membership
• PASC Membership

Other

• TGA
• ARTG

Other Technical Guidance

NICE Decision Support Unit (DSU)

• Introduction to evidence synthesis for decision making
• A general linear modelling framework for pair-wise and network meta-analysis of randomised controlled trials
• Heterogeneity: subgroups, meta-regression, bias and bias-adjustment
• Inconsistency in networks of evidence based on randomised controlled trials 
• Evidence synthesis in the baseline natural history model
• Embedding evidence synthesis in probabilistic cost effectiveness analysis: software choices
• Evidence synthesis of treatment efficacy in decision making: a reviewer’s checklist
• An introduction to the measurement and valuation of health for NICE submissions
• The identification, review and synthesis of health state utility values from the literature
• The use of mapping methods to estimate health state utility values
• Alternatives to EQ-5D for generating health state utility values
• The use of health state utility values in decision models
• Identifying and reviewing evidence to inform the conceptualisation and population of cost-effectiveness models
• Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data
• Cost-effectiveness modelling using patient-level simulation
• Adjusting survival time estimates in the presence of treatment switching
• The use of observational data to inform estimates of treatment effectiveness in technology appraisal: Methods for comparative individual patient data
• Methods for population-adjusted indirect comparisons in submissions to NICE
• Partitioned Survival Analysis as a decision modelling tool
• Multivariate meta-analysis of summary data for combining treatment effects on correlated outcomes and evaluating surrogate endpoints 

Other HTA agencies

• NICE
• NICE Guidelines
• NICE Technology Appraisal (HTA)
• ACE – Agency for Care Effectiveness, SINGAPORE
• AETSA – Andalusian Agency for Health Technology Assessment, SPAIN
• Agenas – The Agency for Regional Healthcare, ITALY
• AHRQ – Agency for Healthcare Research and Quality, USA
• AIHTA – Austrian Institute for Health Technology Assessment, AUSTRIA
• AOTMiT – Agency for Health Technology Assessment and Tariff System, POLAND
• AQuAS – Agència de Qualitat i Avaluació Sanitàries de Catalunya, SPAIN
• AVALIA-T – Galician Agency for Health Technology Assessment, SPAIN
• CADTH – Canadian Agency for Drugs and Technologies in Health, CANADA
• CDE – Center for Drug Evaluation, Taiwan, REPUBLIC OF CHINA
• CEDIT – Comité d’Evaluation et de Diffusion des Innovations Technologiques, FRANCE
• CONITEC – National Committee for Technology Incorporation, BRAZIL
• DEFACTUM – Social & Health Services and Labour Market, DENMARK
• FinCCHTA – Finnish Coordinating Center for Health Technology Assessment, FINLAND
• G-BA – The Federal Joint Committee (Gemeinsamer Bundesausschuss), GERMANY
• GOeG – Gesunheit Österreich GmbH, AUSTRIA
• HAD-Uruguay – Health Assessment Division, Ministry of Public Health, URUGUAY
• HAS – Haute Autorité de Santé, FRANCE
• HTW – Health Technology Wales, UNITED KINGDOM
• IECS – Institute for Clinical Effectiveness and Health Policy, ARGENTINA
• IETS – Instituto de Evaluación Tecnológica en Salud, COLOMBIA
• IETSI – Institute of Health Technology Assessment and Research, PERU
• IHE – Institute of Health Economics, CANADA
• INESSS – Institut national d’excellence en santé et en services, CANADA
• IQWiG – Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, GERMANY
• KCE – Belgian Health Care Knowledge Centre, BELGIUM
• MaHTAS – Health Technology Assessment Section, Ministry of Health Malaysia, MALAYSIA
• NECA – National Evidence-based healthcare Collaborating Agency, KOREA
• NIHR – National Institute for Health Research, UNITED KINGDOM
• NIPH – Norwegian Institute of Public Health, NORWAY
• OSTEBA – Basque Office for Health Technology Assessment, SPAIN
• RCHD – Ministry of Public Health of the Republic of Kazakhstan, Republican Centre for Health Development, KAZAKHSTAN
• SBU – Swedish Agency for Health Technology Assessment and Assessment of Social Services, SWEDEN
• SFOPH – Swiss Federal Office of Public Health, SWITZERLAND
• ZIN – Zorginstituut Nederland, THE NETHERLANDS
• ZonMw – The Netherlands Organisation for Health Research and Development, THE NETHERLANDS